Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

pembrolizumab 183Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 53fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 39Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Registries × Clear all
NCT02454595 2017-09-05

Registry to Measure the Impact of Adding Genomic Testing

Myriad Genetic Laboratories, Inc.

Terminated
116 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡